Penumbra, Inc. (NYSE:PEN) CEO Adam Elsesser sold 10,135 shares of the business’s stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $105.10, for a total transaction of $1,065,188.50. Following the completion of the sale, the chief executive officer now owns 1,133,672 shares in the company, valued at $119,148,927.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Adam Elsesser also recently made the following trade(s):

  • On Tuesday, November 28th, Adam Elsesser sold 10,000 shares of Penumbra stock. The shares were sold at an average price of $103.95, for a total transaction of $1,039,500.00.
  • On Wednesday, November 22nd, Adam Elsesser sold 5,051 shares of Penumbra stock. The shares were sold at an average price of $105.98, for a total transaction of $535,304.98.
  • On Friday, November 17th, Adam Elsesser sold 11,186 shares of Penumbra stock. The shares were sold at an average price of $103.56, for a total transaction of $1,158,422.16.
  • On Monday, November 20th, Adam Elsesser sold 62,862 shares of Penumbra stock. The shares were sold at an average price of $105.15, for a total transaction of $6,609,939.30.
  • On Wednesday, November 15th, Adam Elsesser sold 24,444 shares of Penumbra stock. The shares were sold at an average price of $105.83, for a total value of $2,586,908.52.

Penumbra, Inc. (NYSE:PEN) opened at $105.15 on Thursday. Penumbra, Inc. has a 52-week low of $57.85 and a 52-week high of $116.35.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.07. The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $79.17 million. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. Penumbra’s revenue was up 24.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) EPS. sell-side analysts forecast that Penumbra, Inc. will post -0.15 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PEN. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Penumbra by 10.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock valued at $102,000 after acquiring an additional 114 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Penumbra during the second quarter worth about $213,000. Teacher Retirement System of Texas acquired a new position in shares of Penumbra during the third quarter worth about $214,000. Ameritas Investment Partners Inc. grew its position in shares of Penumbra by 10.8% during the second quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after buying an additional 250 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of Penumbra during the second quarter worth about $252,000. 71.70% of the stock is owned by institutional investors.

PEN has been the subject of several research reports. Zacks Investment Research raised Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. BidaskClub downgraded Penumbra from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. BMO Capital Markets lifted their target price on Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $100.00 target price (up from $94.00) on shares of Penumbra in a research report on Wednesday, August 9th.

TRADEMARK VIOLATION NOTICE: “Penumbra, Inc. (PEN) CEO Sells $1,065,188.50 in Stock” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/11/30/penumbra-inc-pen-ceo-sells-1065188-50-in-stock.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.